Switch theme
Sign up to access all valuation multiples
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.
2014
477
LTM Revenue $215M
LTM EBITDA -$7.7M
$416M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Treace Medical Concepts has a last 12-month revenue of $215M and a last 12-month EBITDA of -$7.7M.
In the most recent fiscal year, Treace Medical Concepts achieved revenue of $209M and an EBITDA of -$42.1M.
Treace Medical Concepts expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Treace Medical Concepts valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $187M | $209M | XXX | XXX | XXX |
| Gross Profit | $114M | $152M | XXX | XXX | XXX |
| Gross Margin | 61% | 73% | XXX | XXX | XXX |
| EBITDA | -$39.0M | -$42.1M | XXX | XXX | XXX |
| EBITDA Margin | -21% | -20% | XXX | XXX | XXX |
| Net Profit | -$42.8M | -$49.5M | XXX | XXX | XXX |
| Net Margin | -23% | -24% | XXX | XXX | XXX |
| Net Debt | $33.2M | $40.0M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Treace Medical Concepts's stock price is $7.
Treace Medical Concepts has current market cap of $422M, and EV of $416M.
See Treace Medical Concepts trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $416M | $422M | XXX | XXX | XXX | XXX | $-0.88 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Treace Medical Concepts has market cap of $422M and EV of $416M.
Treace Medical Concepts's trades at 1.9x LTM EV/Revenue multiple, and -54.0x LTM EBITDA.
Analysts estimate Treace Medical Concepts's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Treace Medical Concepts and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $416M | XXX | XXX | XXX |
| EV/Revenue | 2.0x | XXX | XXX | XXX |
| EV/EBITDA | -9.9x | XXX | XXX | XXX |
| P/E | -7.6x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -8.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpTreace Medical Concepts's NTM/LTM revenue growth is 9%
Treace Medical Concepts's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $0.5M for the same period.
Over next 12 months, Treace Medical Concepts's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Treace Medical Concepts's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Treace Medical Concepts and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -20% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -11% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 71% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 27% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 10% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 107% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Treace Medical Concepts acquired XXX companies to date.
Last acquisition by Treace Medical Concepts was XXXXXXXX, XXXXX XXXXX XXXXXX . Treace Medical Concepts acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Treace Medical Concepts founded? | Treace Medical Concepts was founded in 2014. |
| Where is Treace Medical Concepts headquartered? | Treace Medical Concepts is headquartered in United States of America. |
| How many employees does Treace Medical Concepts have? | As of today, Treace Medical Concepts has 477 employees. |
| Who is the CEO of Treace Medical Concepts? | Treace Medical Concepts's CEO is Mr. John T. Treace. |
| Is Treace Medical Concepts publicy listed? | Yes, Treace Medical Concepts is a public company listed on NAS. |
| What is the stock symbol of Treace Medical Concepts? | Treace Medical Concepts trades under TMCI ticker. |
| When did Treace Medical Concepts go public? | Treace Medical Concepts went public in 2021. |
| Who are competitors of Treace Medical Concepts? | Similar companies to Treace Medical Concepts include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Treace Medical Concepts? | Treace Medical Concepts's current market cap is $422M |
| What is the current revenue of Treace Medical Concepts? | Treace Medical Concepts's last 12-month revenue is $215M. |
| What is the current EBITDA of Treace Medical Concepts? | Treace Medical Concepts's last 12-month EBITDA is -$7.7M. |
| What is the current EV/Revenue multiple of Treace Medical Concepts? | Current revenue multiple of Treace Medical Concepts is 1.9x. |
| What is the current EV/EBITDA multiple of Treace Medical Concepts? | Current EBITDA multiple of Treace Medical Concepts is -54.0x. |
| What is the current revenue growth of Treace Medical Concepts? | Treace Medical Concepts revenue growth between 2023 and 2024 was 12%. |
| Is Treace Medical Concepts profitable? | Yes, Treace Medical Concepts is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
